Loading organizations...
New View Surgical is a technology company.
New View Surgical develops and commercializes the VisionPort System, a medical device designed to enhance minimally invasive surgery. This system integrates multiple surgical functions, providing advanced visualization and instrument access through a single-use port. Its innovative design aims to offer surgeons novel perspectives of the operative field and improve workflow efficiency.
The company was founded in 2009 by Art McKinley, Jesse Plouffe, and Bryce Klontz. Their insight stemmed from identifying limitations in existing minimally invasive surgical techniques, particularly concerning visualization and instrument management. They sought to address the complexities and inefficiencies prevalent in laparoscopic procedures by engineering a unified and simplified approach.
Healthcare professionals performing minimally invasive and laparoscopic surgeries utilize the VisionPort System. New View Surgical's overarching mission is to advance clinical care, streamline operational processes, and reduce associated costs for healthcare systems. The company envisions redefining and simplifying surgical procedures, ultimately improving patient outcomes and practitioner experiences.
New View Surgical has raised $25.6M across 4 funding rounds.
New View Surgical has raised $25.6M in total across 4 funding rounds.
New View Surgical has raised $25.6M in total across 4 funding rounds.
New View Surgical's investors include John Younger, Thomas Testa, Ariel Southeast Angel Partners, Charleston Angel Partners, IAG Capital Partners, Keiretsu Forum, Mid Atlantic Bio Angels, SSIP, Yaniv Sneor, New York Angels, Alumni Ventures, Anderson Angels.
New View Surgical is a medical device company developing the VisionPort System, a single-use surgical imaging and access platform for minimally invasive surgery (MIS). It serves surgeons, operating room staff, and healthcare systems by solving key challenges in laparoscopic procedures, including limited visualization, workflow inefficiencies, dependency on additional team members for camera control, and high equipment costs[1][2][3][4]. The system integrates multiple devices into one disposable unit, enabling surgeon-led control, enhanced operative views, reduced risks, and lower capital/recurring expenses, with the company at Series B-II stage having raised $24.69M total[1].
Growth momentum includes FDA clearance, first commercial case, recognition as a Top 10 Company to Watch in 2023 by Medtech Outlook, and recent leadership hires like Chief Commercial Officer Shane Johnson, positioning it for broader market release[1][4][5].
New View Surgical emerged from an experienced team of medical device innovators addressing unmet needs in MIS visualization, with founding dates cited as 2009 or 2016 across sources—likely reflecting incorporation and active development phases[1][2]. CEO Bryce Klontz leads the effort, emphasizing deep product-market fit through targeted validation rather than broad testing, as shared in investor podcasts and interviews[5]. Pivotal moments include closing a $9M Series B, $12.1M Series B-1 (three years ago), Series A, and investments from groups like New York Angels, Mid Atlantic Bio Angels, and Keiretsu Forum (where it won 'Most Valued Company')[1][5]. Early traction built via FDA clearance and the first commercial use by Dr. David Earle, validating surgeon demand for simplified, efficient tools[5].
New View Surgical rides the growth of minimally invasive surgery, a trend driven by demands for faster recoveries, lower infection risks, and cost efficiencies amid rising healthcare expenditures and aging populations[3]. Timing aligns with post-pandemic OR backlogs and labor shortages, where tools reducing staff dependency gain traction; market forces like single-use device adoption (to curb HAIs) and value-based care favor its dual clinical-economic model[1][4]. It influences the ecosystem by streamlining MIS standardization, potentially accelerating procedure volumes and supporting broader medtech shifts toward disposable, tech-enabled platforms.
Next steps likely include scaling commercial release post-Series B funding, expanding U.S. adoption, and pursuing international clearances to capture global MIS growth[1][5]. Trends like AI-augmented imaging and ambulatory surgery centers will shape its path, amplifying demand for efficient, cost-effective tools amid staffing pressures. Its influence may evolve from niche innovator to category leader, redefining OR dynamics as evidenced by early surgeon endorsements—echoing its core promise of value across clinical, operational, and financial stakeholders[1].
New View Surgical has raised $25.6M across 4 funding rounds. Most recently, it raised $12.1M Series B in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 21, 2022 | $12.1M Series B | John Younger | |
| Nov 2, 2021 | $9.0M Series B | Thomas Testa, John Younger | Ariel Southeast Angel Partners, Charleston Angel Partners, IAG Capital Partners, Keiretsu Forum, Mid Atlantic Bio Angels, SSIP |
| Jun 17, 2019 | $2.5M Series A | Ariel Southeast Angel Partners, Keiretsu Forum, Yaniv Sneor, New York Angels | |
| Sep 1, 2017 | $2.0M Seed | Alumni Ventures, Anderson Angels, Stuart Peterson, Vasudev Bailey, Modern Venture Partners, Rebel Fund |